Investor Fact Sheet

Company Name:

Noxopharm Limited (ABN 50 608 966 123)

Business Description:

Noxopharm Limited (ASX: NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and prevention of septic shock.

Established:

Noxopharm Limited (NOX) was listed on the Australian Securities Exchange on 9 August 2016
Noxopharm Pty Ltd was incorporated in October 2015.

Listings:

Australian Securities Exchange (ASX: NOX)

Shares on Issue:

~288.2m ordinary shares

Board of Directors:

Mr Fred Bart (Non-Executive Chair)
Dr Graham Kelly (CEO and Managing Director)
Mr Peter Marks (Non-Executive Director and Deputy Chairman)
Mr Boris Patkin (Non-Executive Director) 

Company Secretary:

Mr David Franks

Chief Financial Officer:

Mr Shawn van Boheemen

Share Registry:

Automic Registry Services
Level 5, 126 Phillip Street, Sydney, NSW, Australia, 2000

Telephone:

1300 288 664  (within Australia)
+61 2 9698 5414  (outside Australia)

Registered Office:

 Level 20, Tower A, The Zenith 821 Pacific Highway. Chatswood NSW 2067 Australia

Postal:

PO Box 292, Gordon NSW 2072 Australia

Auditors:

William Buck